Meridian Wealth Advisors LLC Has $2.91 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Meridian Wealth Advisors LLC increased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 11.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,531 shares of the medical research company's stock after acquiring an additional 1,760 shares during the period. Meridian Wealth Advisors LLC's holdings in IQVIA were worth $2,914,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in IQV. Norges Bank acquired a new stake in shares of IQVIA during the 4th quarter worth approximately $336,041,000. American Century Companies Inc. boosted its position in shares of IQVIA by 396.0% during the 4th quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock worth $222,987,000 after acquiring an additional 905,960 shares in the last quarter. Invesco Ltd. boosted its position in shares of IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after acquiring an additional 902,226 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in shares of IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock worth $841,461,000 after acquiring an additional 712,958 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in IQVIA by 211.2% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after buying an additional 655,153 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on IQV shares. Robert W. Baird cut their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and cut their target price for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Evercore ISI raised their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday, July 9th. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research report on Monday, May 19th. Finally, Mizuho cut their target price on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research report on Thursday, May 15th. Eight research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Trading Down 1.5%

NYSE IQV traded down $2.37 during mid-day trading on Friday, reaching $160.88. 2,312,787 shares of the stock were exchanged, compared to its average volume of 1,678,075. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The stock has a 50 day simple moving average of $152.90 and a 200-day simple moving average of $170.67. The stock has a market cap of $27.83 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.78 and a beta of 1.30. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.61% and a return on equity of 29.16%. The business's quarterly revenue was up 2.5% on a year-over-year basis. During the same period last year, the company posted $2.54 earnings per share. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.